To include your compound in the COVID-19 Resource Center, submit it here.

Small movement on surrogates

WASHINGTON - The third meeting of the National Task Force on AIDS Drug Development continued its exploration of surrogate markers last week without reaching any conclusions, although the FDA proposed to establish two panels to continue work on the issue.

The agency proposed to form a subcommittee of existing advisory committees devoted to surrogate markers and to form

Read the full 585 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE